Want to see ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
$3.85
-$0.25(-4.33%)
At close: 4:00 PM EDT
$3.85
-$0.25(-4.33%)
Day’s Range― - ―
52-Week Range$2.56 - $10.43
Previous CloseN/A
Volume18.00
Average Volume (3M)18.68K
Market Cap
$2.97M
Enterprise Value$4.97M
Total Cash (Recent Filing)$767.33K
Total Debt (Recent Filing)$77.50K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.61
Shares Outstanding1,822,121
10 Day Avg. Volume8,868
30 Day Avg. Volume18,677
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue104.43
Enterprise Value/Gross Profit-363.08
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Bulls Say, Bears Say
Bulls Say
Advancing CNS PipelineThe lead GABAB PAM candidate has cleared IND-enabling work and is ready to enter clinical development, while several other CNS programs are advancing. This breadth creates multiple opportunities for clinical validation, partnering, and future milestone value rather than relying on one asset.
Broad Platform And Intellectual PropertyRegaining full rights expands Addex’s ability to develop GABAB PAM candidates across indications and negotiate partnerships without the prior license constraint. A young patent portfolio with potential protection through 2044 could support durable exclusivity if the applications are granted.
Extended Cash RunwayThe financing extends the stated cash runway into Q4 2027, giving management more time to advance clinical and preclinical programs before needing additional capital. This improves near-term execution flexibility, although it does not eliminate the company’s longer-term funding needs.
Bears Say
Very Weak And Declining RevenueExtremely low and declining revenue shows that Addex has not yet established meaningful commercial scale and remains dependent on partnering-related economics. Volatile or limited revenue reduces internal funding capacity and makes future operating results heavily dependent on development milestones.
Persistent Cash Burn And Financing DependenceRecurring negative operating and free cash flow means the business is not self-funding its research pipeline. Continued dependence on external financing can dilute shareholders or delay programs, as illustrated by the chronic cough work being ready to start only subject to securing capital.
Shrinking Equity And Financial FlexibilityThe steep decline in equity reflects the cumulative impact of sustained losses and possible dilution or valuation effects, leaving a smaller financial cushion. Although debt is very low, the reduced equity base limits flexibility to absorb setbacks and fund multiple programs internally.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $2.56 and its highest was $10.43 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $2.97M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Sep 28, 2026. The company reported -$1.442 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$1.442 in its last earnings report. Following the earnings report the stock price went down -23.014%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
ADXN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, highlighting a $2.8 million financing, cash runway into Q4 2027, regained rights to the GABAB PAM platform, multiple advancing preclinical and clinical programs, and encouraging chronic cough and substance use disorder data. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash use, a stable CHF 3.4 million net loss, increased share of Neurosterix losses, and the need to secure financing before advancing certain programs.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
67.23% Insiders
0.05% Other Institutional Investors
32.71% Public Companies and
Individual Investors